HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose topical bevacizumab for corneal neovascularization.

AbstractBACKGROUND/AIMS:
Bevacizumab (Avastin), an anti-vascular endothelial growth factor drug, has been successfully used in the recent years to treat ocular pathologies, mostly by intravitreal administration. The aim of the current study was to assess the off-label topical use of high-dose bevacizumab for the treatment of corneal neovascularization.
METHODS:
Seventeen eyes of 17 patients with corneal neovascularization secondary to various pathologies were included. The patients were treated with topical bevacizumab (25 mg/ml) 4 times daily for 2 weeks. The following parameters were evaluated at baseline and on days 3, 7 and 14: visual acuity, slit-lamp examination, intraocular pressure, heart rate and blood pressure. Color photos were obtained at baseline and on day 14.
RESULTS:
Eleven eyes (65%) demonstrated regression of corneal neovascularization and/or clearing of corneal opacification. Adverse ocular events were mild and transient, and included eyelid swelling/chalazion and superficial punctate keratitis.
CONCLUSION:
Treatment with high-dose topical bevacizumab (25 mg/ml) was effective for corneal neovascularization in nearly two thirds of the eyes treated. Adverse ocular side effects were mild and transient.
AuthorsMichael Waisbourd, Eliya Levinger, David Varssano, Elad Moisseiev, Shiri Zayit-Soudri, Adiel Barak, Anat Loewenstein, Irina Barequet
JournalPharmacology (Pharmacology) Vol. 92 Issue 5-6 Pg. 310-4 ( 2013) ISSN: 1423-0313 [Electronic] Switzerland
PMID24335191 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Administration, Ophthalmic
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects, therapeutic use)
  • Bevacizumab
  • Blood Pressure (drug effects)
  • Corneal Neovascularization (drug therapy, pathology)
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Heart Rate (drug effects)
  • Humans
  • Intraocular Pressure (drug effects)
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: